Scrip Reports

Pharmaceutical Pricing, Sales and Distribution in Japan
Market Access

Written by respected industry analyst, Donald Macarthur, this invaluable publication from Scrip Reports focuses on the major areas of pricing and distribution - the main obstacles to achieving pharmaceutical sales success in Japan in the past.

The report supplies a detailed overview of the Japanese market and expert, practical advice on how to penetrate it. It provides key information and advice on major topics, ranging from health insurance and pre- and post-regulatory requirements, to the strategic marketing options available. It also contains invaluable case studies of pharmaceutical pricing strategies in Japan.

Pharmaceutical Pricing, Sales and Distribution in Japan will answer your key questions, including:

How do the systems for new drug pricing and price revision work, and how can I minimise risks and obtain optimum revenue?
How can I optimise distribution?
What recent changes have occurred in Japanese regulatory demands and intellectual property protection?
What further changes are anticipated over the next three years?

This report will bring you completely up-to-date on all recent major developments in Japan, providing you with the in-depth knowledge you need to plan your own successful sales and investment strategies.

Published: April 2000
Reference: BS1066E
Pages: 140
Price: £695/$1,460/¥167,000

CONTENTS SUMMARY

Healthcare system

Regulatory environment

Business environment

Launch price setting
Procedure
Comparator drug
Cost calculation
Premiums
International price adjustment
Rheumatrex - case study
Zoroshin products
Consultation products
Pharmacoeconomics
Publications

Price revision process
Discounting policy
Medical fee increases
Price surveys
Revision results
Market impact
Issues raised
Development of revision methodology
Reasonable zone
Long-listed brands
Consumption tax adjustments
Repricing

Pricing case studies
Cimetidine (and other anti-ulcers);
Fluvoxamine; Paclitaxel
Pravastatin (and other statins);
Quazepam; Tacrolimus

Other cost-containment methods
Bungyo
Revision of medical fees
Claims inspection
Delisting
Prescription limitation
Off-label use
Flat sum reimbursement
Patient co-payment

Other market segments
Generics
OTCs

Distribution
Wholesalers
Pharmacies

Commercial strategies
Development of a multinational presence in Japan
Hurdles facing newcomers
Considerations
Market entry
Making it work
Sales promotion
Maximising opportunities
OTC marketing

Prospects
Political and regulatory environments
Pharmaceutical business environment
Healthcare reform
Cost containment
Pricing & reimbursement
Generics
OTCs
Distribution